Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer

[1]  Y. Shimada,et al.  Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. , 1993, Japanese journal of clinical oncology.

[2]  H. Saka,et al.  Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Langenberg,et al.  Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Kon,et al.  Synthesis and cytostatic activity of the antitumor antibiotic chartreusin derivatives. , 1990, The Journal of antibiotics.

[5]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Neil,et al.  Antitumor activity and preliminary drug disposition studies on chartreusin (NSC 5159). , 1977, Cancer research.

[7]  T. Tsuruo,et al.  Antitumor effects of IST-622, a novel synthetic derivative of chartreusin, against murine and human tumor lines following oral administration , 2004, Cancer Chemotherapy and Pharmacology.

[8]  H. Kunitoh,et al.  Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.